RxDoctor Payments Data

Jeffrey Marogil, MD

Cardiovascular Disease · Glenview, ILNPI 1316147788

Payments from drug & device makers

$2,128in general payments, 2019–2025

Across 89 payments — averaging $23.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$590
  • Pfizer$311
  • Novo Nordisk$267
  • Alnylam Pharmaceuticals Inc.$104
  • Kiniksa Pharmaceuticals International, PLC$99
  • AstraZeneca$96
  • plus $662 from 16 others

What the payments were for

  • Food & beverage$2,128100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,128 in reported general payments places this provider in the 50th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$230,084
Medicare patients
2,761
Services billed
5,376

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban649$727,050
VyndamaxTafamidis11$472,482
EntrestoSacubitril/Valsartan192$232,172
JardianceEmpagliflozin171$138,913
XareltoRivaroxaban126$128,613
OzempicSemaglutide39$45,753
FarxigaDapagliflozin Propanediol45$42,171
Repatha SyringeEvolocumab22$27,250
Repatha SureclickEvolocumab21$18,069
Praluent PenAlirocumab11$13,513
BystolicNebivolol Hcl11$9,563
Metoprolol Succinate507$8,560
Valsartan259$8,144
Atorvastatin Calcium553$5,803
Carvedilol418$4,980

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$311$1,199,532660 claims
NovartisEntresto$590$232,172192 claims
Boehringer IngelheimJardiance$56$138,913171 claims
Johnson & JohnsonXarelto$14$128,613126 claims
Novo NordiskOzempic$267$45,75339 claims
AstraZenecaFarxiga$96$42,17145 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 932 cardiovascular disease providers in Illinois.

Other cardiovascular disease in Glenview

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →